- Home
- SNTI vs CEE Comparison
SNTI vs CEE Comparison
Compare SNTI & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- CEE
- Stock Information
- Founded
- SNTI 2016
- CEE 1990
- Country
- SNTI United States
- CEE Germany
- Employees
- SNTI N/A
- CEE N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- CEE Finance Companies
- Sector
- SNTI Health Care
- CEE Finance
- Exchange
- SNTI Nasdaq
- CEE Nasdaq
- Market Cap
- SNTI 85.3M
- CEE 101.9M
- IPO Year
- SNTI N/A
- CEE N/A
- Fundamental
- Price
- SNTI $3.56
- CEE $15.16
- Analyst Decision
- SNTI Strong Buy
- CEE
- Analyst Count
- SNTI 1
- CEE 0
- Target Price
- SNTI $12.00
- CEE N/A
- AVG Volume (30 Days)
- SNTI 25.9K
- CEE 22.0K
- Earning Date
- SNTI 05-06-2025
- CEE 01-01-0001
- Dividend Yield
- SNTI N/A
- CEE 3.86%
- EPS Growth
- SNTI N/A
- CEE N/A
- EPS
- SNTI N/A
- CEE N/A
- Revenue
- SNTI N/A
- CEE N/A
- Revenue This Year
- SNTI N/A
- CEE N/A
- Revenue Next Year
- SNTI N/A
- CEE N/A
- P/E Ratio
- SNTI N/A
- CEE N/A
- Revenue Growth
- SNTI N/A
- CEE N/A
- 52 Week Low
- SNTI $1.52
- CEE $7.80
- 52 Week High
- SNTI $16.94
- CEE $10.32
- Technical
- Relative Strength Index (RSI)
- SNTI 58.08
- CEE 48.56
- Support Level
- SNTI $3.04
- CEE $14.97
- Resistance Level
- SNTI $3.25
- CEE $15.90
- Average True Range (ATR)
- SNTI 0.23
- CEE 0.56
- MACD
- SNTI 0.04
- CEE -0.13
- Stochastic Oscillator
- SNTI 89.83
- CEE 8.88
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.